MRK highlights pipeline strength and diversification strategy
Management cited a robust pipeline with increased revenue projections, diversification efforts, and disciplined investment in new launches. Oncology progress in sac-TMT and INT was highlighted, alongside new products in ophthalmology and cardiometabolic segments.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.